Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Ocular Therapeutix stock

Learn how to easily invest in Ocular Therapeutix stock.

Ocular Therapeutix Inc is a biotechnology business based in the US. Ocular Therapeutix shares (OCUL) are listed on the NASDAQ and all prices are listed in US Dollars. Ocular Therapeutix employs 228 staff and has a trailing 12-month revenue of around $49.9 million.

How to buy shares in Ocular Therapeutix

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – OCUL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Ocular Therapeutix stock price (NASDAQ: OCUL)

Use our graph to track the performance of OCUL stocks over time.

Ocular Therapeutix shares at a glance

Information last updated 2022-10-03.
Latest market close$4.41
52-week range$2.91 - $12.50
50-day moving average $5.22
200-day moving average $4.91
Wall St. target price$15.79
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.02

Buy Ocular Therapeutix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Ocular Therapeutix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ocular Therapeutix price performance over time

Historical closes compared with the close of $4.41 from 2022-10-04

1 week (2022-09-28) 6.78%
1 month (2022-09-02) -17.11%
3 months (2022-07-05) 1.61%
6 months (2022-04-04) -15.52%
1 year (2021-10-05) -54.72%
2 years (2020-10-05) -47.62%
3 years (2019-10-04) 40.00%
5 years (2017-10-05) 6.34

Ocular Therapeutix financials

Revenue TTM $49.9 million
Gross profit TTM $-10,967,000
Return on assets TTM -23.32%
Return on equity TTM -44.51%
Profit margin -65.11%
Book value $0.86
Market capitalisation $312.1 million

TTM: trailing 12 months

Ocular Therapeutix share dividends

We're not expecting Ocular Therapeutix to pay a dividend over the next 12 months.

Ocular Therapeutix share price volatility

Over the last 12 months, Ocular Therapeutix's shares have ranged in value from as little as $2.91 up to $12.5. A popular way to gauge a stock's volatility is its "beta".

OCUL.US volatility(beta: 1.44)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ocular Therapeutix's is 1.4351. This would suggest that Ocular Therapeutix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Ocular Therapeutix overview

Ocular Therapeutix, Inc. , a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc.

Frequently asked questions

What percentage of Ocular Therapeutix is owned by insiders or institutions?
Currently 1.449% of Ocular Therapeutix shares are held by insiders and 58.37% by institutions.
How many people work for Ocular Therapeutix?
Latest data suggests 228 work at Ocular Therapeutix.
When does the fiscal year end for Ocular Therapeutix?
Ocular Therapeutix's fiscal year ends in December.
Where is Ocular Therapeutix based?
Ocular Therapeutix's address is: 24 Crosby Drive, Bedford, MA, United States, 01730
What is Ocular Therapeutix's ISIN number?
Ocular Therapeutix's international securities identification number is: US67576A1007
What is Ocular Therapeutix's CUSIP number?
Ocular Therapeutix's Committee on Uniform Securities Identification Procedures number is: 67576A100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site